Question: why is ptn stock down?
Answer: Shares of Palatin Technologies (NYSEMKT:PTN) fell over 21% on Tuesday after STAT analyst Adam Feuerstein said that the Food and Drug Administration "made a mistake" by approving the company's new drug, Vyleesi. The drug is intended to treat hypoactive sexual desire disorder (HSDD), or low libido, in women.